Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind placebo-controlled trial of upadacitinib plus topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis
MOH_2018-07-18_002449Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD), sponsored by AbbVie Inc. Started Jul 2018; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on MOH_2018-07-18_002449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-18_002449.